A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults

Sarcopenia Clinical Trial

Official title:

A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults: a Randomised Controlled Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05869526
• Other study ID #: FISHKRILL
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: April 1, 2024

Study information

• Verified date: February 2024
• Source: University of Glasgow
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to compare the effects of Krill Oil and Fish Oil supplementation on muscle function in older adults. The secondary aim is to investigate the mechanisms underlying the beneficial effects previously observed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 61
• Est. completion date: April 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

• Older adults (aged 60 years or older). BMI less than 30kg/m2

Exclusion Criteria:

• Participants (diagnosed and being treated for a pre-existing medical condition (cancer, kidney disease, liver disease, diabetes mellitus and cardiovascular disease, uncontrolled hypertension, gait disturbances limiting the ability to perform assessments of muscle function, dementia, affecting muscles known to use drugs (e.g., steroids). History of allergy to fish or fish oil and regular consumption of more than1portion of oily fish per week or use of fish oil or krill oil supplements will also be excluded.

Related Conditions & MeSH terms

• Sarcopenia

Intervention

Dietary Supplement:
• Fish oil
EPA rich fish oil
• Kril oil
Superba Krill Oil
• Vegetable oil
Mixed vegetable oil

Locations

Country	Name	City	State
United Kingdom	Stuart Robert Gray	Glasgow	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Step Time (Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cycle Time (Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Length (CM)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Stride Length (CM)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	H-H Base Support (CM)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Single Support (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Double Support (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Swing (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Stance (%GC)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step/ Extremity Ratio	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Toe In/ Out (deg)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Distance (CM)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Ambulation Time (Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Velocity (CM/Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Mean Normalized Velocity	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Number of Steps	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cadence (Steps/Min)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Time Differential (Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Step Length Differential (CM)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Other	Cycle Time Differential (Sec)	Measured during a 4m walk using a gaitrite mat	Change from baseline to 16 weeks
Primary	Change in knee extensor maximal isometric torque ( MVC)	Knee extensor maximal isometric torque measured during a maximal voluntary contraction	Change from baseline to 16 weeks
Secondary	Change in fat mass	Whole body fat mass measured by measured via bio-electrical impedance	Change from baseline to 16 weeks
Secondary	Change in lean mass	Whole body lean mass measured by measured via bio-electrical impedance	Change from baseline to 16 weeks
Secondary	Blood sample	Red Blood Cell Omega-3 levels	Change from baseline to 16 weeks
Secondary	Change in Grip strength	Grip strength measured with a hand held dynamometer	Change from baseline to 16 weeks
Secondary	Change in Muscle thickness	Vastus lateralis muscle thickness measured by ultrasound	Change from baseline to 16 weeks
Secondary	Force steadiness during submaximal isometric knee extensor contractions	Measured by using intramuscular iEMG	Change from baseline to 16 weeks
Secondary	Neuromuscular Junction (NMJ)	Measured by iEMG	Change from baseline to 16 weeks
Secondary	Change in gait speed	Time taken to walk 4 metres at a normal walking pace	Change from baseline to 16 weeks
Secondary	Change in Chair rise time	A 30-second sit-to-stand test measured functional abilities	Change from baseline to 16 weeks